Coherus Biosciences (8C5) Stock Statistics & Valuation Metrics
Total Valuation
Coherus Biosciences has a market cap or net worth of EUR 114.67M. The enterprise value is EUR 165.61M.
- Market Cap
- EUR 114.67M
- Enterprise Value
- EUR 165.61M
Share Statistics
Coherus Biosciences has 154,500,960 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 154,500,960
- Owned by Insiders
- 1.24%
- Owned by Institutions
- 27.60%
Financial Efficiency
Coherus Biosciences’s return on equity (ROE) is -2.79 and return on invested capital (ROIC) is -151.77%.
- Return on Equity (ROE)
- -2.79
- Return on Assets (ROA)
- -0.66
- Return on Invested Capital (ROIC)
- -151.77%
- Return on Capital Employed (ROCE)
- -1.54
- Revenue Per Employee
- 292.86K
- Profits Per Employee
- -1.18M
- Employee Count
- 144
- Asset Turnover
- 0.16
- Inventory Turnover
- 5.59
Valuation Ratios
The current PE Ratio of Coherus Biosciences is -0.73. Coherus Biosciences’s PEG ratio is -0.03.
- PE Ratio
- -0.73
- PS Ratio
- 2.27
- PB Ratio
- 1.91
- Price to FCF
- -0.47
- Price to Operating Cash Flow
- -0.48
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, Coherus Biosciences had revenue of 42.17M and earned -170.29M in profits. Earnings per share was -1.45.
- Revenue
- 42.17M
- Gross Profit
- 24.43M
- Operating Income
- -179.53M
- Pretax Income
- -183.12M
- Net Income
- -170.29M
- EBITDA
- -170.20M
- Earnings Per Share (EPS)
- -1.45
Cash Flow
In the last 12 months, operating cash flow was -243.92M and capital expenditures 0, giving a free cash flow of -243.92M billion.
- Operating Cash Flow
- -243.92M
- Free Cash Flow
- -243.92M
- Free Cash Flow per Share
- -1.58
Dividends & Yields
Coherus Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -206.10%
- Earnings Yield
- -110.43%
Stock Price Statistics
- Beta
- 1.14
- 52-Week Price Change
- -46.56%
- 50-Day Moving Average
- 1.04
- 200-Day Moving Average
- 1.30
- Relative Strength Index (RSI)
- 36.54
- Average Volume (3m)
- 200
Important Dates
Coherus Biosciences upcoming earnings date is Nov 09, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 05, 2026
- Next Earnings Date
- Nov 09, 2026
- Ex-Dividend Date
- ―
Financial Position
Coherus Biosciences as a current ratio of 1.46, with Debt / Equity ratio of 66.11%
- Current Ratio
- 1.46
- Quick Ratio
- 1.43
- Debt to Market Cap
- 0.22
- Net Debt to EBITDA
- 0.29
- Interest Coverage Ratio
- -19.95
Taxes
In the past 12 months, Coherus Biosciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Coherus Biosciences EV to EBITDA ratio is -0.49, with an EV/FCF ratio of -0.30.
- EV to Sales
- 1.44
- EV to EBITDA
- -0.49
- EV to Free Cash Flow
- -0.30
- EV to Operating Cash Flow
- -0.30
Balance Sheet
Coherus Biosciences has EUR 105.31M in cash and marketable securities with EUR 37.71M in debt, giving a net cash position of EUR 67.60M billion.
- Cash & Marketable Securities
- EUR 105.31M
- Total Debt
- EUR 37.71M
- Net Cash
- EUR 67.60M
- Net Cash Per Share
- EUR 0.44
- Tangible Book Value Per Share
- EUR 0.10
Margins
Gross margin is 63.55%, with operating margin of -307.43%, and net profit margin of -257.10%.
- Gross Margin
- 63.55%
- Operating Margin
- -307.43%
- Pretax Margin
- -316.37%
- Net Profit Margin
- -257.10%
- EBITDA Margin
- -291.46%
- EBIT Margin
- -298.54%
Analyst Forecast
The average price target for Coherus Biosciences is EUR 6.92, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 6.92
- Price Target Upside
- 782.16% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- -66.77%
- EPS Growth Forecast
- 31.35%
Scores
- Smart Score
- 8
- AI Score
- ―
